Preclinical studies: How much can we rely on?

Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Volumn 5, Issue SUPPL. 1, 2004, Pages 22-25

  Rothstein, Jeffrey D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; MINOCYCLINE; MUTANT PROTEIN; NEW DRUG; NIFEDIPINE; PROSTAGLANDIN; RILUZOLE; SUPEROXIDE DISMUTASE; VASCULOTROPIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ASTROCYTE; CLINICAL STUDY; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG RESEARCH; EXPERIMENTAL MODEL; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MICROGLIA; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; OLIGODENDROGLIA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RODENT; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; SURVIVAL; TRANSGENIC ANIMAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS;

EID: 6444223252     PISSN: 14660822     EISSN: None     Source Type: Journal    
DOI: 10.1080/17434470410020012     Document Type: Review

References (19)

1. Camu W, Henderson CE. Rapid purification of embryonic rat motor neurons: an in vitro model for studying MND/ALS pathogenesis. J Neurol Sci 1994; 124(suppl): 73-74.
2. Rothstein JD, Jin L, Dykes-Hoberg M et al. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA 1993; 90: 6591-6595.
3. Henderson CE. Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis: potential and pitfalls. Adv Neurol 1995; 68: 235-240.
4. Wong PC, Pardo CA, Borchelt DR et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995; 14: 1105-1116.
5. Bruijn LI, Becher MW, Lee MK et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997; 18: 327-338.
6. Gurney ME, Pu H, Chiu AY et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775.
7. Howland DS, Liu J, She Y et al. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci USA 2002; 99: 1604-1609.
8. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-819.
9. Gong YH, Parsadanian AS, Andreeva A et al. Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motor neuron degeneration. J Neurosci 2000; 20: 660-665.
10. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motor neurons does not cause motor neuron pathology or motor neuron disease. J Neurosci 2002; 22: 4825-4832.
11. Raoul C, Estevez AG, Nishimune H et al. Motor neuron death triggered by a specific pathway downstream of Fas. Potentiation by ALS-linked SOD1 mutations. Neuron 2002; 35: 1067-1083.
12. Ferrante RJ, Andreassen OA, Jenkins BG et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci 2000; 20: 4389-4397.
13. Gurney ME, Cutting FB, Zhai P et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39: 147-157.
14. Groeneveld GJ, Veldink JH, van der Tweel I. A randomized sequential trial of creatine monohydrate in amyotrophic lateral sclerosis. Ann Neurol 2003; 53: 437-445.
15. Kriz J, Gowing G, Julien J. An efficient three-drug cocktail for motor neuron disease induced by mutant superoxide dismutase. Ann Neurol 2003; 53: 429-436.
16. Chen M, Ona VO, Li M et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease. Nat Med 2000; 6: 797-801.
17. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2002; 10: 268-278.
18. Van den BL, Tilkin P, Lemmens G et al. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport 2002; 13: 1067-1070.
19. Heemskerk J, Tobin AJ, Ravina B. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials. Nat Neurosci 2002; 5(suppl): 1027-1029.